ClinicalTrials.gg
CompletedNCT05261126Updated Dec 9, 2024Results posted

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

A Phase 2 interventional study of Enclitide Chloride and Placebo in Hypercholesterolemia and Familial Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 63 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.

Enrollment
17th of 27
381 · median 500
Started
2022
with 2 others
Phase 2
4 of 29
none open now
Registered
20th of 29
by date

Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 17th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 2, and was the 20th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypercholesterolemia by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of enclitide chloride, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of enclitide chloride tested in this study is superior to placebo on percent change from baseline in LDL-C at Week 8.

03

Conditions studied

  • Hypercholesterolemia
  • Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of clinical atherosclerotic cardiovascular disease (ASCVD), or has an ASCVD risk equivalent and/or a 10-year risk of having an ASCVD event ≥5.0%, AND has a corresponding LDL-C that falls within the protocol-specified range at screening.
  • Treatment with a stable dose of one or more lipid-lowering therapies for ≥30 days before screening, or has not received treatment with any lipid-lowering therapy for ≥30 days before screening.
  • A female participant is not pregnant or breastfeeding, not a woman of (WOCBP) or is a WOCBP and agrees to follow guidance during the intervention period and for at least 8 weeks after the last dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • History of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria.
  • History of nephrotic syndrome.
  • History of unstable angina, a myocardial infarction, percutaneous transluminal coronary angioplasty, , or stroke within 3 months before Screening.
  • Has poorly controlled diabetes mellitus, defined as (A1C) ≥9.0% at Screening.
  • History of ≤3 years before screening, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, which have no timeframe limitations relative to screening.
  • Currently participating in or has previously participated in an interventional clinical study within 3 months before Screening.
  • Has moderate or greater renal insufficiency.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    Enclitide Chloride 6 mg

    Participants will receive 6 mg of enlicitide chloride orally QD for 8 weeks

    Drug: Enclitide Chloride

  • Experimental
    Enclitide Chloride 12 mg

    Participants will receive 12 mg of enlicitide chloride orally QD for 8 weeks

    Drug: Enclitide Chloride

  • Experimental
    Enclitide Chloride 18 mg

    Participants will receive 18 mg of enlicitide chloride orally QD for 8 weeks

    Drug: Enclitide Chloride

  • Experimental
    Enclitide Chloride 30 mg

    Participants will receive 30 mg of enlicitide chloride orally QD for 8 weeks

    Drug: Enclitide Chloride

  • Placebo comparator
    Placebo

    Participants will receive enlicitide chloride-matching placebo orally QD for 8 weeks

    Drug: Placebo

Interventions

  • Enclitide Chloride administered orally

    Also known as: MK-0616

  • DrugPlacebo

    Placebo matching enclitide chloride administered orally

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8

    Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in LDL-C. Based on a constrained longitudinal analysis (cLDA) model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in LDL-C at week 8 was reported.

    Time frame: Baseline and up to Week 8

  2. Percentage of Participants Who Experienced One or More Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one AE was reported.

    Time frame: Up to approximately 17 Weeks

  3. Percentage of Participants Who Discontinued Study Intervention Due to AEs

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to AEs was reported.

    Time frame: Up to approximately 9 Weeks

Secondary outcomes

  1. Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 8

    Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in ApoB. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in ApoB at week 8 was reported.

    Time frame: Baseline and up to Week 8

  2. Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 8

    Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in non-HDL-C. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in non-HDL-C at week 8 was reported.

    Time frame: Baseline and up to Week 8

  3. Percentage of Participants With LDL-C Value at Goal at Week 8

    LDL-C goal was defined as: LDL-C \<70 mg/dL (\<1.81 mmol/L) in participants with clinical atherosclerotic cardiovascular disease (ASCVD), LDL-C \<100 mg/dL (\<2.59 mmol/L) in participants with an ASCVD risk-equivalent and/or a 10-year risk of having an ASCVD event that is ≥7.5%, OR LDL-C \<130 mg/dL (\<3.37mmol/L) in participants with a 10-year risk of having an ASCVD event that is ≥5.0% and \<7.5%. The percentage of participants with LDL-C value at goal at week 8 were reported.

    Time frame: Week 8

07

Results

Posted Dec 6, 2023

Participant flow

Of 668 participants screened for inclusion, 381 were randomized 1:1:1:1:1 to receive MK-0616 6 mg, 12 mg, 18 mg, 30 mg, or placebo. Of the 381 randomized participants, one participant did not receive at least one dose of study intervention.

Participant flow — Overall Study
MilestoneMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Started7776767676
Treated7776767675
Completed7576747474
Not completed20222
Withdrew: Death00100
Withdrew: Lost to follow-up00001
Withdrew: Physician decision10000
Withdrew: Screen failure00001
Withdrew: Withdrawal by subject10110
Withdrew: Not recorded00010

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8

Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in LDL-C. Based on a constrained longitudinal analysis (cLDA) model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in LDL-C at week 8 was reported.

Time frame:
Baseline and up to Week 8
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8
Percentage ChangeMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8-40.0 (-45.2 to -34.8)-54.5 (-59.8 to -49.2)-57.9 (-63.2 to -52.6)-59.7 (-65.0 to -54.5)1.2 (-4.1 to 6.5)
Statistical analysis
  • MK-0616 6 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -41.2 · 95% CI -47.8 to -34.7MK-0616 6 mg minus Placebo
  • MK-0616 12 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -55.7 · 95% CI -62.3 to -49.1MK-0616 12 mg minus Placebo
  • MK-0616 18 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -59.1 · 95% CI -65.7 to -52.5MK-0616 18 mg minus Placebo
  • MK-0616 30 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -60.9 · 95% CI -67.6 to -54.3MK-0616 30 mg minus Placebo
PrimaryPercentage of Participants Who Experienced One or More Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one AE was reported.

Time frame:
Up to approximately 17 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced One or More Adverse Events (AEs)
Percentage of ParticipantsMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Percentage of Participants Who Experienced One or More Adverse Events (AEs)44.239.543.442.144.0
Statistical analysis
  • MK-0616 6 mg vs Placebo · Difference in percentage: 0.2 · 95% CI -15.5 to 15.8MK-0616 6 mg minus Placebo
  • MK-0616 12 mg vs Placebo · Difference in percentage: -4.5 · 95% CI -20.0 to 11.2MK-0616 12 mg vs Placebo
  • MK-0616 18 mg vs Placebo · Difference in percentage: -0.6 · 95% CI -16.3 to 15.1MK-0616 18 mg vs Placebo
  • MK-0616 30 mg vs Placebo · Difference in percentage: -1.9 · 95% CI -17.5 to 13.8MK-0616 30 mg minus Placebo
PrimaryPercentage of Participants Who Discontinued Study Intervention Due to AEs

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to AEs was reported.

Time frame:
Up to approximately 9 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Intervention Due to AEs
Percentage of ParticipantsMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Percentage of Participants Who Discontinued Study Intervention Due to AEs2.60.02.62.61.3
SecondaryPercent Change From Baseline in Apolipoprotein B (ApoB) at Week 8

Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in ApoB. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in ApoB at week 8 was reported.

Time frame:
Baseline and up to Week 8
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 8
Percentage ChangeMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 8-32.8 (-37.6 to -27.9)-45.8 (-50.7 to -40.9)-48.7 (-53.6 to -43.8)-51.8 (-56.7 to -47.0)0.0 (-4.9 to 4.9)
Statistical analysis
  • MK-0616 6 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -32.8 · 95% CI -38.6 to -26.9MK-0616 6 mg minus Placebo
  • MK-0616 12 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -45.8 · 95% CI -51.7 to -39.9MK-0616 12 mg minus Placebo
  • MK-0616 18 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -48.7 · 95% CI -54.6 to -42.8MK-0616 18 mg minus Placebo
  • MK-0616 30 mg vs Placebo · cLDA · p = <0.001 · Difference in least square means: -51.8 · 95% CI -57.7 to -45.9MK-0616 30 mg minus Placebo
SecondaryPercent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 8

Blood samples were collected at baseline and after 8 weeks of treatment to assess mean percent change in non-HDL-C. The least square mean and 95% CI were obtained from fitting a cLDA model including terms for treatment, time, baseline statin intensity, baseline renal function, and the interaction of treatment by time. The percent change from baseline in non-HDL-C at week 8 was reported.

Time frame:
Baseline and up to Week 8
Reported as:
Least squares mean · Percentage Change
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 8
Percentage ChangeMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 8-34.4 (-39.6 to -29.2)-49.0 (-54.3 to -43.7)-51.8 (-57.1 to -46.4)-54.3 (-59.6 to -49.1)1.5 (-3.9 to 6.8)
Statistical analysis
  • MK-0616 6 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -35.9 · 95% CI -42.4 to -29.4MK-0616 6 mg minus Placebo
  • MK-0616 12 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -50.5 · 95% CI -57.0 to -44.0MK-0616 12 mg minus Placebo
  • MK-0616 18 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -53.2 · 95% CI -59.7 to -46.7MK-0616 18 mg minus Placebo
  • MK-0616 30 mg vs Placebo · cLDA · p = <0.001 · Difference in least squares means: -55.8 · 95% CI -62.3 to -49.3MK-0616 30 mg minus Placebo
SecondaryPercentage of Participants With LDL-C Value at Goal at Week 8

LDL-C goal was defined as: LDL-C \<70 mg/dL (\<1.81 mmol/L) in participants with clinical atherosclerotic cardiovascular disease (ASCVD), LDL-C \<100 mg/dL (\<2.59 mmol/L) in participants with an ASCVD risk-equivalent and/or a 10-year risk of having an ASCVD event that is ≥7.5%, OR LDL-C \<130 mg/dL (\<3.37mmol/L) in participants with a 10-year risk of having an ASCVD event that is ≥5.0% and \<7.5%. The percentage of participants with LDL-C value at goal at week 8 were reported.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With LDL-C Value at Goal at Week 8
Percentage of ParticipantsMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Percentage of Participants With LDL-C Value at Goal at Week 880.585.590.890.89.3
Statistical analysis
  • MK-0616 6 mg vs Placebo · Miettinen & Nurminen · p = <0.001 · Difference in percentage: 69.2 · 95% CI 56.2 to 79.0MK-0616 6 mg minus Placebo
  • MK-0616 12 mg vs Placebo · Miettinen & Nurminen method · p = <0.001 · Difference in percentage: 75.2 · 95% CI 62.9 to 84.0MK-0616 12 mg minus Placebo
  • MK-0616 18 mg vs Placebo · Miettinen & Nurminen method · p = <0.001 · Difference in percentage: 79.2 · 95% CI 67.1 to 87.1MK-0616 18 mg minus Placebo
  • MK-0616 30 mg vs Placebo · Miettinen & Nurminen method · p = <0.001 · Difference in percentage: 79.5 · 95% CI 67.9 to 87.4MK-0616 30 mg minus Placebo

Adverse events

Collected over Up to approximately 17 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-0616 6 mg0/77 (0%)1/77 (1.3%)11/77 (14.3%)
MK-0616 12 mg0/76 (0%)3/76 (3.9%)13/76 (17.1%)
MK-0616 18 mg1/76 (1.3%)2/76 (2.6%)15/76 (19.7%)
MK-0616 30 mg0/76 (0%)2/76 (2.6%)8/76 (10.5%)
Placebo0/76 (0%)0/75 (0%)15/75 (20%)
Most frequent serious events
Most frequent serious events
EventMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
Acute left ventricular failureCardiac disorders0/770/761/760/760/75
CholecystitisHepatobiliary disorders0/771/760/760/760/75
COVID-19Infections and infestations0/771/760/760/760/75
Multiple injuriesInjury, poisoning and procedural complications0/770/760/761/760/75
Road traffic accidentInjury, poisoning and procedural complications0/770/761/760/760/75
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/770/760/761/760/75
Post-traumatic stress disorderPsychiatric disorders0/770/760/761/760/75
Respiratory distressRespiratory, thoracic and mediastinal disorders0/770/761/760/760/75
Deep vein thrombosisVascular disorders0/771/760/760/760/75
Non-cardiac chest painGeneral disorders1/770/760/760/760/75
Most frequent other events
Most frequent other events
EventMK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlacebo
COVID-19Infections and infestations6/771/765/764/767/75
FatigueGeneral disorders0/773/761/760/765/75
DyspepsiaGastrointestinal disorders1/775/763/760/761/75
DiarrhoeaGastrointestinal disorders5/771/763/761/761/75
NauseaGastrointestinal disorders1/771/764/762/760/75
ArthralgiaMusculoskeletal and connective tissue disorders0/774/761/762/761/75

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlaceboTotal
Mean61.7 ± 10.362.0 ± 9.462.0 ± 9.260.9 ± 10.260.6 ± 9.361.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)MK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlaceboTotal
Female3835393838188
Male3941373838193
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlaceboTotal
Hispanic or Latino2629313137154
Not Hispanic or Latino5146454538225
Unknown or Not Reported010012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlaceboTotal
American Indian or Alaska Native4552521
Asian18131113863
Native Hawaiian or Other Pacific Islander000000
Black or African American4529424
White4948554454250
More than one race2538523
Unknown or Not Reported000000
Randomization Strata: Background Statin Dose
Randomization Strata: Background Statin Dose(Participants)MK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlaceboTotal
No Statin Therapy3029313030150
Low- to Moderate-intensity Statin Therapy2727262626132
High-intensity Statin Therapy202019202099
Randomization Strata: Renal Function
Randomization Strata: Renal Function(Participants)MK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlaceboTotal
eGFR ≥60 ml/min/1.73 m^27172727171357
eGFR <60 ml/min/1.73 m^26445524
Baseline Low-density Lipoprotein Cholesterol (LDL-C)
Baseline Low-density Lipoprotein Cholesterol (LDL-C)(mg/dL)MK-0616 6 mgMK-0616 12 mgMK-0616 18 mgMK-0616 30 mgPlaceboTotal
Mean116.5 ± 37.0117.3 ± 36.4123.7 ± 35.1119.4 ± 36.7120.7 ± 28.3119.5 ± 34.8
08

Study locations

63 sites
  • Westside Medical Associates of Los Angeles ( Site 0026)
    Beverly Hills, California 90211, United States
  • Clinical Trials Research ( Site 0007)
    Sacramento, California 95821, United States
  • National Research Institute (NRI) - Santa Ana ( Site 0024)
    Santa Ana, California 92704, United States
  • Excel Medical Clinical Trials ( Site 0042)
    Boca Raton, Florida 33434, United States
  • Alliance for Multispecialty Research, LLC ( Site 0050)
    Coral Gables, Florida 33134, United States
  • ForCare Clinical Research ( Site 0017)
    Tampa, Florida 33613, United States
  • Healthcare Research Network - Chicago ( Site 0037)
    Flossmoor, Illinois 60422, United States
  • Midwest Institute For Clinical Research ( Site 0036)
    Indianapolis, Indiana 46260, United States
  • Cotton O'Neil Mulvane ( Site 0022)
    Topeka, Kansas 66606, United States
  • L-MARC Research Center ( Site 0003)
    Louisville, Kentucky 40213, United States
  • The University of Mississippi Medical Center-Clinical Research and Trials Unit ( Site 0028)
    Jackson, Mississippi 39216, United States
  • Jubilee Clinical Research ( Site 0047)
    Las Vegas, Nevada 89106, United States
  • New Mexico Clinical Research & Osteoporosis Center ( Site 0032)
    Albuquerque, New Mexico 87106, United States
  • Mid Hudson Medical Research ( Site 0004)
    New Windsor, New York 12553, United States
  • altoona center for clinical research ( Site 0045)
    Duncansville, Pennsylvania 16635, United States
  • Piedmont Research Partners ( Site 0005)
    Fort Mill, South Carolina 29707, United States
  • Dallas Diabetes Research Center ( Site 0012)
    Dallas, Texas 75230, United States
  • Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0051)
    Houston, Texas 77030, United States
  • Northeast Clinical Research of San Antonio ( Site 0014)
    San Antonio, Texas 78233, United States
  • National Clinical Research, Inc-research office ( Site 0019)
    Richmond, Virginia 23294, United States
  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen ( Site 0504)
    München, Bayern 80336, Germany
  • Kardiologische Gemeinschaftspraxis ( Site 0502)
    Nuremberg, Bayern 90402, Germany
  • Ambulantes Herzzentrum Kassel ( Site 0501)
    Kassel, Hessen 34121, Germany
  • Universitätsklinikum Leipzig ( Site 0500)
    Leipzig, Sachsen 04103, Germany
  • Charité Campus Virchow-Klinikum ( Site 0505)
    Berlin, 13353, Germany
  • Chubu Rosal Hospital ( Site 1612)
    Nagoya, Aichi 455-8530, Japan
  • Kyoto Okamoto Memorial Hospital ( Site 1611)
    Kuse-gun Kumiyama-cho, Kyoto 613-0034, Japan
  • Kitada Clinic ( Site 1604)
    Osaka-city, Osaka 538-0044, Japan
  • Medical Corporation Heishinkai OCROM Clinic ( Site 1600)
    Suita-shi, Osaka 565-0853, Japan
  • Seiwa Clinic ( Site 1605)
    Adachi-ku, Tokyo 123-0845, Japan
  • meiwa hospital ( Site 1602)
    Chiyoda-ku, Tokyo 101-0041, Japan
  • Heishinkai Medical Group ToCROM Clinic ( Site 1601)
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Sekino Hospital ( Site 1603)
    Toshimaku, Tokyo 171-0014, Japan
  • Keimyung University Dongsan Hospital ( Site 1703)
    Daegu, Taegu-Kwangyokshi 42601, Korea, Republic of
  • Seoul National University Hospital ( Site 1702)
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System ( Site 1701)
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center ( Site 1700)
    Seoul, 06351, Korea, Republic of
  • Bio Investigación AMARC, S.C. ( Site 0204)
    Ciudad de México, Distrito Federal 11410, Mexico
  • Hospital Angeles Mocel ( Site 0209)
    Mexico City, Distrito Federal 11850, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0212)
    Mexico City, Distrito Federal 14080, Mexico
  • Instituto Jalisciense de Investigacion en Diabetes y Obesidad-Endocrinology ( Site 0205)
    Guadalajara, Jalisco 04460, Mexico
  • Unidad de Investigaci�n Cl�nica Cardiometabolica de Occident-Unidad de Investigación Clínica Cardio
    Guadalajara, Jalisco 44150, Mexico
  • Unidad biomedica avanzada monterrey-Clinical Trials ( Site 0200)
    Monterrey, Nuevo Leon 64460, Mexico
  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares-Subinvestigation ( Site 0201)
    Ciudad Madero, Tamaulipas 89440, Mexico
  • Hospital Angeles Xalapa-Internal Medicine-Cardiology ( Site 0202)
    Xalapa, Veracruz 91193, Mexico
  • Medical Care and Research SA de CV ( Site 0211)
    Merida, Yucatan 97070, Mexico
  • Centro de Atención e Investigación Clínica ( Site 0214)
    Aguascalientes, 20129, Mexico
  • Akershus Universitetssykehus-Hjertemedisinsk Avdeling ( Site 0705)
    Lørenskog, Akershus 1478, Norway
  • Nordlandssykehuset ( Site 0709)
    Bodø, Nordland 8005, Norway
  • Stavanger Universitetssykehus ( Site 0706)
    Stavanger, Rogaland 4011, Norway
  • Sykehuset i Vestfold-Hjerteseksjonen ( Site 0703)
    Tønsberg, Vestfold 3103, Norway
  • Oslo Universitetssykehus Aker-Preventiv kardiologi Aker ( Site 0704)
    Oslo, 0316, Norway
  • Oslo Universitetssykehus Rikshospitalet-Kardiologisk avdeling ( Site 0702)
    Oslo, 0372, Norway
  • Oslo Universitetssykehus Ullevål-Hjertemedisinsk avdeling, Ullevål ( Site 0701)
    Oslo, 0450, Norway
  • Oslo Universitetssykehus Aker-Lipidklinikken ( Site 0700)
    Oslo, 0586, Norway
  • Ege University Medicine of Faculty-Cardilogy Department ( Site 1003)
    Bornova, Izmir 35100, Turkey
  • Hacettepe Universitesi ( Site 1002)
    Ankara, 06230, Turkey
  • Eskisehir Osmangazi University-Cardiology ( Site 1000)
    Eskisehir, 26480, Turkey
  • Royal Free Hospital ( Site 1311)
    London, England NW32QG, United Kingdom
  • Queen Elizabeth University Hospital-Glasgow Clinical Research Facility ( Site 1310)
    Glasgow, Glasgow City G51 4TF, United Kingdom
  • Layton Medical Centre ( Site 1303)
    Blackpool, Lancashire FY3 7EN, United Kingdom
  • William Harvey Heart Centre ( Site 1308)
    London, London, City Of EC1M 5PZ, United Kingdom
  • Walsall Manor Hospital ( Site 1309)
    West Midlands, Walsall WS2 9PS, United Kingdom
09

References and documents

Publications

  • Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, Mendizabal G, Mitchel Y, Catapano AL. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. J Am Coll Cardiol. 2023 Apr 25;81(16):1553-1564. doi: 10.1016/j.jacc.2023.02.018. Epub 2023 Mar 6. PubMed 36889610 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Nov 2022, 8 months.

Results were first posted in Dec 2023, 1 year after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 8 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 2, 2022
StartActual
Mar 10, 2022
Primary completionActual
Nov 28, 2022
CompletionActual
Nov 28, 2022
Results first posted
Dec 6, 2023
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05261126
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Mar 10, 2022
Primary completion
Nov 28, 2022
Completion
Nov 28, 2022
Results posted
Dec 6, 2023
Last update
Dec 9, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion